Curis, Inc. (CRIS): Price and Financial Metrics


Curis, Inc. (CRIS)

Today's Latest Price: $1.35 USD

0.05 (3.85%)

Updated Nov 23 4:00pm

Add CRIS to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

CRIS Stock Summary

  • Curis Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 6.61% of US listed stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -1.14 for Curis Inc; that's greater than it is for only 5.78% of US stocks.
  • With a year-over-year growth in debt of 1,837.9%, Curis Inc's debt growth rate surpasses 98.79% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to Curis Inc, a group of peers worth examining would be VIE, LOGC, ORMP, PULM, and LPTX.
  • Visit CRIS's SEC page to see the company's official filings. To visit the company's web site, go to www.curis.com.

CRIS Stock Price Chart Interactive Chart >

Price chart for CRIS

CRIS Price/Volume Stats

Current price $1.35 52-week high $3.59
Prev. close $1.30 52-week low $0.62
Day low $1.29 Volume 1,194,261
Day high $1.36 Avg. volume 1,346,445
50-day MA $1.18 Dividend yield N/A
200-day MA $1.09 Market Cap 79.40M

Curis, Inc. (CRIS) Company Bio


Curis, Inc. engages in the discovery and development of drug candidates for the treatment of human cancers. The company was founded in 2000 and is based in Lexington, Massachusetts.


CRIS Latest News Stream


Event/Time News Detail
Loading, please wait...

CRIS Latest Social Stream


Loading social stream, please wait...

View Full CRIS Social Stream

Latest CRIS News From Around the Web

Below are the latest news stories about Curis Inc that investors may wish to consider to help them evaluate CRIS as an investment opportunity.

Curis to Present at Upcoming Investor Conferences

LEXINGTON, Mass. , Sept. 10, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS ), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer , President and Chief Executive Officer of Curis, will provide a company overview at two upcoming investor conferences: … Full story available on Benzinga.com

Benzinga | September 10, 2020

Curis, Inc. (CRIS) CEO Jim Dentzer on Q2 2020 Results - Earnings Call Transcript

Curis, Inc. (CRIS) Q2 2020 Earnings Conference Call August 04, 2020 04:30 PM ET Company Participants Bill Steinkrauss - Chief Financial Officer Jim Dentzer - President & Chief Executive Officer Bob Martell - Head of R&D Conference Call Participants Alethia Young - Cantor Soumit Roy - JonesTrading Yale Jen -...

SA Transcripts on Seeking Alpha | August 5, 2020

Curis Doses First Patient in Phase 1 Study of CA-4948 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the first patient has been dosed in its Phase 1 trial evaluating CA-4948, a novel, small molecule IRAK4 kinase inhibitor, in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS) with spliceosome mutations, such as SF3B1 and U2AF1, that drive expression of the long isoform of IRAK4 (IRAK4-L). IRAK4 plays an essential role in the toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways, and these pathways are frequently dysregulated in patients with AML and MDS.

Yahoo | July 7, 2020

Edited Transcript of CRIS earnings conference call or presentation 12-May-20 8:30pm GMT

Q1 2020 Curis Inc Earnings Call

Yahoo | June 22, 2020

The Only Way To Play Curis

Source: Company website Companies like Curis (CRIS) attract speculators, traders and pumpers because of the relatively easy way the stock price can be temporarily manipulated to give it a big boost, or in some cases, respond to press releases issued to generate a quick boost in the share price. Many...

Gary Bourgeault | June 12, 2020

Read More 'CRIS' Stories Here

CRIS Price Returns

1-mo 17.39%
3-mo 18.42%
6-mo 64.61%
1-year -18.18%
3-year -69.93%
5-year -90.18%
YTD -20.59%
2019 146.38%
2018 -80.29%
2017 -77.27%
2016 5.84%
2015 94.00%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9728 seconds.